These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29401308)

  • 1. Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?
    Burbelo PD; Price RW; Hagberg L; Hatano H; Spudich S; Deeks SG; Gisslén M
    J Infect Dis; 2018 Mar; 217(7):1024-1032. PubMed ID: 29401308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.
    Joseph SB; Kincer LP; Bowman NM; Evans C; Vinikoor MJ; Lippincott CK; Gisslén M; Spudich S; Menezes P; Robertson K; Archin N; Kashuba A; Eron JJ; Price RW; Swanstrom R
    Clin Infect Dis; 2019 Sep; 69(8):1345-1352. PubMed ID: 30561541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.
    Anderson AM; Muñoz-Moreno JA; McClernon DR; Ellis RJ; Cookson D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Franklin DR; Heaton RK; Grant I; Letendre SL;
    J Infect Dis; 2017 Jan; 215(1):105-113. PubMed ID: 27789723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.
    Yilmaz A; Price RW; Spudich S; Fuchs D; Hagberg L; Gisslén M
    J Acquir Immune Defic Syndr; 2008 Feb; 47(2):168-73. PubMed ID: 17971711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic of CSF and serum biomarkers in HIV-1 subtype C encephalitis with CNS genetic compartmentalization-case study.
    de Almeida SM; Rotta I; Ribeiro CE; Oliveira MF; Chaillon A; de Pereira AP; Cunha AP; Zonta M; Bents JF; Raboni SM; Smith D; Letendre S; Ellis RJ
    J Neurovirol; 2017 Jun; 23(3):460-473. PubMed ID: 28247269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy.
    Dahl V; Gisslen M; Hagberg L; Peterson J; Shao W; Spudich S; Price RW; Palmer S
    J Infect Dis; 2014 May; 209(10):1618-22. PubMed ID: 24338353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
    Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
    Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
    Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
    Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma.
    Hellmuth J; Slike BM; Sacdalan C; Best J; Kroon E; Phanuphak N; Fletcher JLK; Prueksakaew P; Jagodzinski LL; Valcour V; Robb M; Ananworanich J; Allen IE; Krebs SJ; Spudich S
    J Infect Dis; 2019 Nov; 220(12):1885-1891. PubMed ID: 30668739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular analysis of cerebrospinal fluid: potential for the study of HIV-1 infection of the central nervous system.
    Cinque P; Bestetti A; Morelli P; Presi S
    J Neurovirol; 2000 May; 6 Suppl 1():S95-S102. PubMed ID: 10871772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection.
    Cepok S; von Geldern G; Nolting T; Grummel V; Srivastava R; Zhou D; Hartung HP; Adams O; Arendt G; Hemmer B
    Ann Neurol; 2007 Nov; 62(5):458-67. PubMed ID: 17703460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
    Spudich S; Lollo N; Liegler T; Deeks SG; Price RW
    J Infect Dis; 2006 Dec; 194(12):1686-96. PubMed ID: 17109340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection.
    Hare CB; Pappalardo BL; Busch MP; Karlsson AC; Phelps BH; Alexander SS; Bentsen C; Ramstead CA; Nixon DF; Levy JA; Hecht FM
    Clin Infect Dis; 2006 Mar; 42(5):700-8. PubMed ID: 16447118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA.
    Gianella S; von Wyl V; Fischer M; Niederoest B; Battegay M; Bernasconi E; Cavassini M; Rauch A; Hirschel B; Vernazza P; Weber R; Joos B; Günthard HF;
    Antivir Ther; 2011; 16(4):535-45. PubMed ID: 21685541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal detection of cerebrospinal fluid escape after initiation of antiretroviral therapy in acute HIV-1 infection.
    Handoko R; Chan P; Jagodzinski L; Pinyakorn S; Ubolyam S; Phanuphak N; Sacdalan C; Kroon E; Dumrongpisutikul N; Paul R; Valcour V; Ananworanich J; Vasan S; Spudich S;
    AIDS; 2021 Apr; 35(5):777-782. PubMed ID: 33306551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid CXCL10 is associated with the presence of low level CSF HIV during suppressive antiretroviral therapy.
    Anderson AM; Kundu S; Tang B; Vaida F; Okwuegbuna O; McClernon D; Cherner M; Deutsch R; Cookson D; Crescini M; Grant I; Zetterberg H; Blennow K; Gisslen M; Ellis RJ; Letendre SL
    J Neuroimmunol; 2021 Apr; 353():577493. PubMed ID: 33571816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus-1 RNA levels in cerebrospinal fluid exhibit a set point in clinically stable patients not receiving antiretroviral therapy.
    Ellis RJ; Childers ME; Zimmerman JD; Frost SD; Deutsch R; McCutchan JA;
    J Infect Dis; 2003 Jun; 187(11):1818-21. PubMed ID: 12751041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse of Symptomatic Cerebrospinal Fluid HIV Escape.
    Ferretti F; De Zan V; Gerevini S; Turrini F; Boeri E; Gianotti N; Hasson H; Lazzarin A; Cinque P
    Curr HIV/AIDS Rep; 2020 Oct; 17(5):522-528. PubMed ID: 32875516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Immunodeficiency Virus (HIV)-Antibody Repertoire Estimates Reservoir Size and Time of Antiretroviral Therapy Initiation in Virally Suppressed Perinatally HIV-Infected Children.
    Rocca S; Zangari P; Cotugno N; De Rossi A; Ferns B; Petricone D; Rinaldi S; Giaquinto C; Bernardi S; Rojo P; Rossi P; Pahwa S; Nastouli E; Palma P;
    J Pediatric Infect Dis Soc; 2019 Nov; 8(5):433-438. PubMed ID: 30169837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.